- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03827629
A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers
January 31, 2019 updated by: INSYS Therapeutics Inc
A Phase 1, Open-Label, Randomized, Crossover, Comparative Bioavailability Study of Naloxone Nasal Spray and Naloxone Hydrochloride Intramuscular Injection in Healthy Volunteers
The main objective of this study is to compare early exposures of two test formulations of Naloxone Nasal Spray with the reference formulation of Naloxone HCl IM Injection under fasted conditions.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78217
- Worldwide Clinical Trials
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A minimum body weight of 50 kg and a body mass index (BMI) between 18.0 and 32.0 kilogram per square meter (kg/m2)
- A seated blood pressure between 90 and 140 millimeters of mercury (mmHg) systolic/50 and 90 mmHg diastolic (inclusive)
- Female subjects had a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening
Exclusion Criteria:
- A known allergy or history of significant adverse reaction to naloxone, other opioids or related compounds, or to any of the excipients.
- Any documented clinically significant infection, injury, or illness within 1 month prior to screening.
- An active malignancy of any type, or had been diagnosed with cancer within 5 years prior to screening.
- A documented history of alcohol or drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within 2 years prior to screening. Alcohol abuse was defined as greater than 14 drinks per week.
- Positive serology test for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at screening.
- A positive urine test result for alcohol, drugs, or cotinine at screening or check-in.
- A condition that the Investigator believed would have interfered with the ability to provide informed consent or comply with study instructions, or that could confound the interpretation of the study results or put the subject at undue risk.
- Used any opioids for 30 days prior to Day 1.
- Required treatment with monoamine oxidase inhibitors (MAOIs) within 30 days prior to Day 1 and during the study.
- Presence of an ongoing upper respiratory infection, rhinitis, rhinorrhea, or nasal congestion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Treatment Sequence A-B-C
Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
|
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone HCl IM injection following a 10 hour fast.
|
Experimental: Cohort 2: Treatment Sequence B-C-A
Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
|
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone HCl IM injection following a 10 hour fast.
|
Experimental: Cohort 3: Treatment Sequence C-A-B
Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
|
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone HCl IM injection following a 10 hour fast.
|
Experimental: Cohort 4: Treatment Sequence A-C-B
Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
|
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone HCl IM injection following a 10 hour fast.
|
Experimental: Cohort 5: Treatment Sequence C-B-A
Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
|
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone HCl IM injection following a 10 hour fast.
|
Experimental: Cohort 6: Treatment Sequence B-A-C
Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
|
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone nasal spray following a 10 hour fast.
Participants received naloxone HCl IM injection following a 10 hour fast.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma Concentration of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 1 hour post-dose
|
Pre-dose and at multiple time points up to 1 hour post-dose
|
Partial Area Under the Concentration Curve (AUC) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 1 hour post-dose
|
Pre-dose and at multiple time points up to 1 hour post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Elimination Half-Life (t1/2) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Area Under the Curve from Time 0 to the Last Measured Concentration (AUC0-t) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Area Under the Curve from Time 0 to Infinity (AUC0-inf) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Percentage of AUC0-inf Obtained by Extrapolation (AUCextrap) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Maximum Plasma Concentration (Cmax) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Time to Reach Maximum Plasma Concentration (Tmax) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Last Quantifiable Concentration (Clast) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Time of the Last Quantifiable Concentration (Tlast) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Time Prior to the First Measurable (Non-Zero) Concentration (Tlag) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Elimination Rate Constant (λz) of Unconjugated Naloxone
Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose
|
Pre-dose and at multiple time points up to 24 hours post-dose
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to Day 10
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation.
An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product.
A serious AE (SAE) is any AE that results in death, is life threatening, requires hospitalization or prolongs existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is medically significant or requires intervention.
|
Day 1 up to Day 10
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 7, 2017
Primary Completion (Actual)
August 16, 2017
Study Completion (Actual)
August 16, 2017
Study Registration Dates
First Submitted
January 31, 2019
First Submitted That Met QC Criteria
January 31, 2019
First Posted (Actual)
February 1, 2019
Study Record Updates
Last Update Posted (Actual)
February 1, 2019
Last Update Submitted That Met QC Criteria
January 31, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INS012-17-108
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
-
AbbVieCompletedHealthy VolunteerUnited States
Clinical Trials on Treatment A: Naloxone Nasal Spray
-
INSYS Therapeutics IncCompleted
-
Food and Drug Administration (FDA)Spaulding Clinical Research LLCCompletedClinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal NaloxoneHealthy Subjects | Pharmacokinetics | Opioid AntagonistUnited States
-
State University of New York - Upstate Medical...Binghamton UniversityCompletedHarm Reduction | Opioid-use Disorder | NaloxoneUnited States
-
Anhui Palo Alto Pharmaceuticals, Inc.CompletedAllergic RhinitisChina
-
Huahui HealthCompleted
-
Pocket Naloxone CorpCompleted
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic RhinitisUnited States
-
Finnish Institute for Health and WelfareUnknownNaloxone | Gambling Disorder | Opioid Antagonist | Pathological GamblingFinland
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States